DiaCarta Unveils Innovative MPOX Testing Solutions
DiaCarta, Inc., a well-respected name in in-vitro diagnostics, is ramping up its efforts to meet the rising demand for mpox (previously known as monkeypox) detection. Building on its successful track record of providing COVID-19 testing kits, the company is broadening its scope to include mpox along with other infectious diseases. This strategic shift is a direct response to the World Health Organization's declaration of a public health emergency due to mpox outbreaks around the globe.
Immediate Need for Improved MPOX Testing
With the number of mpox cases on the rise, DiaCarta is working closely with distributors and laboratories to ensure their innovative mpox testing kits reach more healthcare professionals. This initiative aims to speed up the detection and treatment of patients. As new cases emerge worldwide, the demand for an efficient and effective testing solution has never been more urgent.
FDA-EUA Approval: A Major Advancement
DiaCarta’s mpox test, which has received Emergency Use Authorization from the FDA, underscores their commitment to precision medicine. This test is specifically designed to detect the latest variants of the mpox virus, clade I and clade II, ensuring both accuracy and reliability. Importantly, it can be used with the widely adopted qPCR machines that played a crucial role in COVID-19 testing. This compatibility allows healthcare facilities to seamlessly incorporate mpox testing into their existing workflows without the need for additional equipment costs.
CEO's Vision for the Future
Adam (Aiguo) Zhang, the CEO of DiaCarta, highlighted the importance of their testing kit in addressing the current health crisis. "We are committed to tackling mpox and are collaborating with global partners to make our FDA-EUA-approved testing kits available to more doctors and patients. We invite distributors, laboratories, and public health authorities worldwide to join us in enhancing our mpox testing initiatives," Adam stated.
Current Landscape of MPOX Cases
Recent data shows a staggering 160% increase in new mpox cases in certain regions, along with a concerning 19% rise in related fatalities compared to last year. The Democratic Republic of Congo has been particularly hard hit, but the virus has also spread to numerous other countries across Africa, Europe, and Asia. These alarming trends underscore the urgent need for widespread testing and prompt medical responses.
Global Outreach and Support
DiaCarta is actively involved in outreach efforts to ensure that their testing kits reach healthcare providers on the front lines. By collaborating with healthcare facilities, the company aims to strengthen the global response to the mpox crisis. This community-focused approach ensures preparedness and resilience in managing public health challenges.
About DiaCarta
DiaCarta is a pioneering molecular in-vitro diagnostics company dedicated to improving patient care through innovative diagnostic solutions. By utilizing advanced technologies such as XNA and SuperbDNA™, DiaCarta enhances detection sensitivity and simplifies the diagnostic process. Committed to quality, the company is ISO-certified, GMP-compliant, and offers CLIA-certified laboratory services. For further information, visit www.diacarta.com.
Contact Information
For any inquiries, please reach out via phone at (510) 878 6662 or email at [email protected].
Frequently Asked Questions
What is the significance of DiaCarta's MPOX testing kits?
DiaCarta's MPOX testing kits are groundbreaking as they offer FDA-EUA-approved solutions that enable rapid and accurate detection of mpox, facilitating timely patient treatment.
How does DiaCarta's MPOX test work?
The MPOX test from DiaCarta employs qPCR machines that are commonly used for COVID-19 testing, making it a cost-effective option for laboratories by eliminating the need for new equipment.
Why is there an increased demand for MPOX testing?
The World Health Organization's declaration of a public health emergency regarding mpox outbreaks has significantly heightened the need for effective testing solutions globally.
What market regions are currently affected by MPOX?
At present, new mpox cases are rising sharply in Africa and have also begun to emerge in Europe and Asia, creating an urgent need for testing and healthcare responses.
How can healthcare facilities obtain DiaCarta's MPOX testing kits?
Healthcare facilities can directly contact DiaCarta to inquire about acquiring MPOX testing kits to enhance their diagnostic capabilities.
